Triamcinolone Acetonide Nasal Spray Rx
Generic Name and Formulations:
Triamcinolone acetonide 55mcg/spray; aqueous nasal spray.
Various generic manufacturers
Indications for Triamcinolone Acetonide Nasal Spray:
Seasonal and perennial allergic rhinitis.
2 sprays in each nostril once daily. Reduce dose as condition improves.
<2yrs: not established. 2–5yrs: 1 spray in each nostril once daily. 6–12yrs: 1 spray in each nostril once daily; max 2 sprays in each nostril once daily. Reduce dose as condition improves.
Maintain regular regimen. Respiratory tract tuberculosis. Infections (eg, ocular herpes simplex). If exposed to measles or chickenpox, consider anti-infective prophylactic therapy. Avoid use in patients with recent nasal ulcers, surgery, or trauma. Reevaluate if no improvement in 3 weeks. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with topical corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, depression). Monitor for growth suppression in children. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually), changes in vision or increased intraocular pressure, and candida infection or other nasal mucosal changes. Avoid eyes. Pregnancy (Cat.C). Nursing mothers.
Pharyngitis, epistaxis, flu syndrome, cough increased, bronchitis, headache, pharyngolaryngeal pain, nasopharyngitis, abdominal upper pain, GI upset; glaucoma/cataracts, impaired wound healing, reduced growth velocity in children.
Nasal spray—16.5g (120 sprays)
Clinical Pain Advisor Articles
- Chronic Neuropathic Pain Updated Classification by IASP for ICD-11
- Buprenorphine-Naloxone Found to Be More Cost-Effective Than Extended-Release Naltrexone
- Ultrasound-Guided C2 Coblation May Be Effective for Cervicogenic Headache
- Meta-Analysis of Opioid Treatment for Chronic Noncancer Pain
- Opioids Found to Increase Risk for Community-Acquired Pneumonia, Particularly in HIV
- Reviewing the Use of Buprenorphine in Perioperative Pain Management
- Early Physical Therapy for Musculoskeletal Pain May Reduce Opioid Use
- External Trigeminal Nerve Stimulation May Alleviate Migraine Pain
- IASP Updates Diagnosis Criteria for Chronic Primary Pain for ICD-11
- Galcanezumab Provides Persistent Preventive Effects in Episodic, Chronic Migraine
- Comparable Analgesia With Low-Dose IV Ketamine, Morphine for Acute Pain
- Benzodiazepines, if Prescribed, May Not Affect Methadone Treatment Retention
- When Opioid Prescribing Guidelines Become Rules
- IV Fluid Confers No Significant Treatment Effect on Migraine Pain
- American Headache Society Releases Position Statement on Novel Preventive and Acute Migraine Treatments